(HealthDay)—The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.
Aug 07, 2014
5 / 5 (1) | 0
Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop responding and progress, ...
Aug 08, 2014
4.5 / 5 (2) | 0